xBiologix is a pre-seed start-up developing color biopsies to screen malignant tumors for drug targets. Using color biopsies, clinicians can prescribe the right drugs for each patient within days after surgery. Currently, more than 65% of patients diagnosed with solid tumors do not respond to prescribed treatments, primarily because predicting treatment response depends on simultaneously visualizing dozens of tumor features.

Three in five people alive today will be diagnosed with a solid tumor in their lifetime— nearly every family is directly affected by these cancers. Color biopsies will change the trajectory of cancer treatment by cutting the number of failed solid tumor treatments in half.

xBiologix is first to market with a new, patented synthetic biology that builds on the

2022 Nobel

Prize for click chemistry

, enabling the unsurpassed advantages of

these color microscopy reagents in

clinics

. And our technology lets customers use instruments many already own— making timely treatment decisions clinically, financially and economically viable.

We all want more effective cancer treatments. The fastest way for us to start helping real patients is to get our reagents into clinical trials for new cancer drugs. Developing reagents for use in clinical trials will help the more than 1.2M patients who enroll in solid tumor trials annually and generate revenue. xBiologix currently has opportunities for its reagents in three clinical trials. Drug developers using xBiologix’s reagents benefit because our reagents screen for patients who respond to their therapies, significantly improving clinical trial performance. Patients benefit because they are matched with drugs that are more likely to be effective. It’s a win-win, but to get started we need support from a few investors.

xBiologix expects to see potential exits as it grows from three to thirty customers in 18-24 months— after closing its current $1.5M raise. Healthy margins are projected to produce $10M in profit on $16M in revenue. Both strategic and technology exits are possible in a three-to-five year timeframe. Strategic exits , ranging from $50-$150M involve

spatial biology

company mergers as the $2B market (TAM/2029) consolidates. A noteworthy technology exit recently occurred when Johnson and Johnson purchased a small biotech company for $2.4B; and Novartis agreed to pay $1.7B for services from a seed-stage company similar to xBiologix in December 2025.

If you’re a mission-driven investor, xBiologix is a unique opportunity to change the lives of the nearly 2M people diagnosed with solid tumor cancers in the US every year by helping more patients get the therapy that works sooner, and by helping promising new drugs reach the right patients faster.